Read by QxMD icon Read

Ankylosing spondyloarthritis

Miranda van Lunteren, Zineb Ez-Zaitouni, Anoek de Koning, Hanne Dagfinrud, Roberta Ramonda, Lennart Jacobsson, Robert Landewé, Désirée van der Heijde, Floris A van Gaalen
OBJECTIVE: In early axial spondyloarthritis (axSpA), data are lacking about the relationship between disease activity and health-related quality of life (HRQOL). We assessed and quantified the association between change in Ankylosing Spondylitis Disease Activity Score (ASDAS) and HRQOL over time in early axSpA. METHODS: Baseline and 1-year data of patients with axSpA fulfilling the Assessment of Spondyloarthritis international Society (ASAS) classification criteria from the SPondyloArthritis Caught Early (SPACE) cohort were analyzed...
March 15, 2018: Journal of Rheumatology
Sovira Tan, Michael M Ward
PURPOSE OF REVIEW: Computed tomography (CT) is increasingly being used in ankylosing spondylitis (AS) for imaging the spine and sacroiliac joint (SIJ). We review new insights to diagnosis and evaluation revealed by the use of CT. RECENT FINDINGS: Studies using low-dose CT in AS to detect syndesmophytes can image the entire spine, but semiquantitative scoring of the scans by human readers decreases the reliability and validity of this method. The thoracic spine is the segment most involved with syndesmophytes...
March 13, 2018: Current Opinion in Rheumatology
Filip Van den Bosch, Philip J Mease, Joachim Sieper, Dominique L Baeten, Yinglin Xia, Su Chen, Aileen L Pangan, In-Ho Song
Objectives: Describe efficacy and safety of 3 years of adalimumab treatment in patients with peripheral spondyloarthritis (pSpA) and identify predictors of remission. Methods: Patients with pSpA were randomised to adalimumab 40 mg every other week or placebo for 12 weeks; a 144-week open-label extension followed (NCT01064856). Remission was assessed by the Peripheral SpA Response Criteria (PSpARC) and Ankylosing Spondylitis Disease Activity Score inactive disease (ASDAS ID)...
2018: RMD Open
Mohammad H Derakhshan, Himanshu Pathak, Debbie Cook, Sally Dickinson, Stefan Siebert, Karl Gaffney
Objectives: There have been significant advances in axial spondyloarthritis (axSpA), with implications for service delivery. We evaluated the state of axSpA rheumatology services and how people with axSpA perceive their care. Methods: An online patient survey was emailed to all members of the National Ankylosing Spondylitis Society and advertised widely via social media. Separately, a Web-based questionnaire about axSpA services was sent to rheumatologists at all 172 acute hospital trusts in the UK...
February 23, 2018: Rheumatology
X J Ji, K Sun, Z Y Hu, Y Zhang, Y P Ma, Z Sun, K P Li, J Zhu, J L Zhang, F Huang
Objective: The aim of this study was to set up a large, longitudinal and prospective database to compare the clinical manifestations in human leucocyte antigen (HLA)-B(27) positive and negative patients with ankylosing spondylitis(AS) based on real-world evidence in Chinese population. Methods: A total of 897 outpatients with confirmed AS were recruited consecutively by smart management system for spondyloarthritis (SMSP) from April 13, 2016 to June 6, 2017 in Chinese PLA General Hospital from 30 provinces and autonomous regions...
March 1, 2018: Zhonghua Nei Ke za Zhi [Chinese Journal of Internal Medicine]
Praveena Chiowchanwisawakit, Wanruchada Katchamart, Manathip Osiri, Pongthorn Narongroeknawin, Parawee Chevaisrakul, Tasanee Kitumnuaypong, Boonjing Siripaitoon, Worawit Louthrenoo
OBJECTIVE: This study aimed to evaluate the long-term effectiveness and safety of the first anti-tumor necrosis factor α therapy (TNFi) and to identify the associated factors of drug discontinuation in patients with spondyloarthritis. METHODS: This was a retrospective cohort study. Patients with spondyloarthritis who were prescribed the first TNFi between December 2009 and October 2014 in the Rheumatic Disease Prior Authorization registry were enrolled. Baseline clinical data were retrieved...
March 7, 2018: Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases
Sayam Dubash, Dennis McGonagle, Helena Marzo-Ortega
Axial spondyloarthritis (axSpA) is a chronic inflammatory condition that encompasses ankylosing spondylitis (AS) as well as non-radiographic axial disease (nr-axSpA) and can lead to chronic pain, structural damage and disability. The introduction of tumour necrosis factor inhibitor (TNFi) drugs for AS heralded a new era of drug therapeutics for what was previously a largely untreatable disease. This has now been expanded with the licensing of secukinumab, an interleukin 17A (IL-17A) inhibitor for the treatment of AS...
March 2018: Therapeutic Advances in Chronic Disease
Janneke J de Winter, Marleen G van de Sande, Niklas Baerlecken, Inger Berg, Roberta Ramonda, Désirée van der Heijde, Floris A van Gaalen, Torsten Witte, Dominique L Baeten
BACKGROUND: Anti-CD74 IgG antibodies are reported to be elevated in patients with axial spondyloarthritis (axSpA). This study assessed the diagnostic value of anti-CD74 antibodies in patients with early axSpA. METHODS: Anti-CD74 IgG and IgA antibodies were first measured in an exploratory cohort of patients with radiographic axSpA (138 patients with ankylosing spondyloarthritis (AS)) and 57 healthy controls and then were measured in patients with early axSpA (n = 274) and with non-SpA chronic back pain (CBP) (n = 319), participating in the spondyloarthritis caught early (SPACE) prospective cohort study of patients under 45 years old with early back pain (for ≥ 3 months, but ≤ 2 years)...
March 1, 2018: Arthritis Research & Therapy
Maureen Dubreuil, Joachim Sieper
The delay between symptom onset and diagnosis in axial spondyloarthritis (axSpA) remains unacceptably long; recently estimated to still be more than 6 years.1 Accumulating data demonstrates that early treatment with TNF-inhibitors reduces both disease activity and radiographic progression in ankylosing spondylitis, the prototypic form of axSpA.2 3 To encourage timely and correct diagnosis and enable early treatment, strategies to better identify patients with axSpA have been studied in several populations.4 This article is protected by copyright...
February 22, 2018: Arthritis & Rheumatology
Yukai Huang, Weiming Deng, Shaoling Zheng, Fan Feng, Zhixiang Huang, Qidang Huang, Xin Guo, Zhengping Huang, Xuechang Huang, Xia Pan, Tianwang Li
BACKGROUND: Axial spondyloarthritis (axSpA) is a progressive, chronic, inflammatory skeletal disorder affecting the spine and sacroiliac joints. Many studies have shown that neutrophils, lymphocytes, monocytes, platelets, and red blood cells (RBCs) play important roles in the inflammatory process of axSpA. Neutrophils to lymphocytes ratio (NLR) and red blood cell distribution width (RDW) have been reported to be simple and inexpensive markers to indicate the disease activity of axSpA...
February 19, 2018: International Immunopharmacology
Riccardo Terenzi, Sara Monti, Giulia Tesei, Linda Carli
The term spondyloarthritis (SpA) represents a condition characterised by a broad spectrum of clinical manifestations, laboratory abnormalities and imaging features; in particular, SpA is an inflammatory condition in which both peripheral and axial joints might be affected. The majority of people with this disease have either psoriatic arthritis or axial spondyloarthritis, which includes ankylosing spondylitis. Less common subgroups are enteropathic SpA, which is associated with inflammatory bowel diseases (Crohn's disease and ulcerative colitis), reactive arthritis, which can occur in people following gastrointestinal or genitourinary infections and undifferentiated SpA, that does not meet the diagnostic criteria of the other subgroups at onset, but that may evolve to do so later...
January 2018: Clinical and Experimental Rheumatology
A de Koning, J W Schoones, D van der Heijde, F A van Gaalen
Axial spondyloarthritis (axSpA) is a common inflammatory arthritis of the sacroiliac joints and the spine. The best-known and most studied form of axSpA is ankylosing spondylitis. In this review, we provide a brief overview of the pathophysiology of axSpA. In addition, we performed a quantitative text analysis of reviews on the pathogenesis of axSpA published in the last ten years to establish the current consensus in various fields of research into the pathogenesis of axSpA. There appears to be broad consensus on genetic risk factors and the involvement of the immune system in the initiation phase of the disease although little consensus was found on which specific immune cells drive disease...
February 20, 2018: European Journal of Clinical Investigation
Simon Krabbe, Mikkel Østergaard, Iris Eshed, Inge J Sørensen, Bente Jensen, Jakob M Møller, Lone Balding, Ole R Madsen, Karsten Asmussen, Grith Eng, Niklas R Jørgensen, Susanne J Pedersen
OBJECTIVE: To investigate whether adalimumab (ADA) reduces whole-body (WB-) magnetic resonance imaging (MRI) indices for inflammation in the entheses, peripheral joints, sacroiliac joints, spine, and the entire body in patients with axial spondyloarthritis (axSpA). METHODS: An investigator-initiated, randomized, placebo-controlled, double-blinded 48-week followup trial included 49 patients with axSpA, who had Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≥ 4...
February 15, 2018: Journal of Rheumatology
Monika Hebeisen, Regula Neuenschwander, Almut Scherer, Pascale Exer, Ulrich Weber, Giorgio Tamborrini, Raphael Micheroli, Lukas M Wildi, Pascal Zufferey, Michael J Nissen, Peter M Villiger, Jürg Bernhard, Axel Finckh, Irene E van der Horst-Bruinsma, Joachim Sieper, Robert Landewé, Désirée van der Heijde, Adrian Ciurea
OBJECTIVE: To investigate sex differences in connection with the effectiveness of tumor necrosis factor inhibitors (TNFi) in patients with ankylosing spondylitis (AS). METHODS: A total of 440 patients with AS (294 men; 146 women) initiating a first TNFi in the prospective Swiss Clinical Quality Management Cohort were included. We evaluated the proportion of patients achieving the 20% and 40% improvement in the Assessment of Spondyloarthritis international Society criteria (ASAS20 and ASAS40) as well as Ankylosing Spondylitis Disease Activity Score (ASDAS) improvement and status scores at 1 year...
February 15, 2018: Journal of Rheumatology
Linda A Bradbury, Kelly A Hollis, Benoît Gautier, Sateesh Shankaranarayana, Philip C Robinson, Nivene Saad, Kim-Anh Lê Cao, Matthew A Brown
OBJECTIVE: We tested the discriminatory capacity of diffusion-weighted magnetic resonance imaging (DWI) and its potential as an objective measure of treatment response to tumor necrosis factor inhibition in ankylosing spondylitis (AS). METHODS: Three cohorts were studied prospectively: (1) 18 AS patients with Bath Ankylosing Spondylitis Disease Activity Index > 4, and erythrocyte sedimentation rate > 25 and/or C-reactive protein > 10 meeting the modified New York criteria for AS; (2) 20 cases of nonradiographic axial spondyloarthritis (nr-axSpA) as defined by the Assessment of Spondyloarthritis international Society (ASAS) criteria; and (3) 20 non-AS patients with chronic low back pain, aged between 18 and 45 years, who did not meet the imaging arm of the ASAS criteria for axSpA...
February 15, 2018: Journal of Rheumatology
Michele Maria Luchetti, Francesco Ciccia, Chiara Avellini, Devis Benfaremo, Giuliana Guggino, Alessia Farinelli, Monia Ciferri, Matteo Rossini, Silvia Svegliati, Tatiana Spadoni, Laura Bolognini, Giammarco Fava, Piergiorgio Mosca, Rosaria Gesuita, Edlira Skrami, Giovanni Triolo, Armando Gabrielli
OBJECTIVE: The early diagnosis of inflammatory bowel disease (IBD)-associated spondyloarthritis (SpA/IBD) in patients affected by IBD represents a major topic in clinical practice; in particular, to date there are no available serum biomarkers revealing the presence of joint inflammation in these patients. Sclerostin (SOST), an antagonist of the Wnt/β-catenin pathway, and antisclerostin-immunoglobulin G (anti-SOST-IgG) have been recently studied in patients with ankylosing spondylitis (AS) as a putative marker of disease activity...
February 1, 2018: Journal of Rheumatology
Ennio Lubrano, Fabio Massimo Perrotta, Maria Manara, Salvatore D'Angelo, Olga Addimanda, Roberta Ramonda, Leonardo Punzi, Ignazio Olivieri, Carlo Salvarani, Antonio Marchesoni
OBJECTIVE: The aim of this study was to evaluate the influence of sex on response to treatment and disease remission in patients with axial spondyloarthritis (axSpA). METHODS: In this retrospective multicenter study, patients with axSpA, according to the Assessment of Spondyloarthritis international Society (ASAS) criteria for axSpA, and treated with adalimumab, etanercept, golimumab, or infliximab, were studied. We compared clinical characteristics, patient-reported outcomes, disease activity, function, and response to treatment in male and female patients with this disease...
February 2018: Journal of Rheumatology
A Bremander, E Haglund, S Bergman, M Ndosi
OBJECTIVES: The aim of the present study was to validate the Swedish version of the educational needs assessment tool (SwENAT) in undifferentiated spondyloarthritis (USpA) and use it to study the educational needs of patients with USpA. METHODS: This was a cross-sectional study, recruiting a random sample of patients with USpA from a hospital register in Sweden. Educational needs data were collected, together with disease activity and function indices (Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] and Bath Ankylosing Spondylitis Functional Index [BASFI])...
February 7, 2018: Musculoskeletal Care
Philip J Mease, Désirée van der Heijde, Chitra Karki, Jacqueline B Palmer, Mei Liu, Renganayaki Pandurengan, Yujin Park, Jeffrey D Greenberg
OBJECTIVE: To describe the characteristics of patients with ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) in the United States. METHODS: Demographics, clinical characteristics, patient-reported outcomes, and treatment characteristics of patients with AS and nr-axSpA were assessed at the time of enrollment in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. AS was defined as patients who fulfilled the 1984 modified New York criteria for AS; nr-axSpA was defined as all other patients with axSpA who did not fulfill the radiologic criterion...
February 6, 2018: Arthritis Care & Research
Alison Wadeley, Emily Clarke, Shaaron Leverment, Raj Sengupta
The study aims were to assess the prevalence of good or poor sleep in a cohort of axial spondyloarthritis patients and to investigate its correlation with a range of objectively and subjectively measured variables in order to develop a model for distinguishing good from poor sleepers. Five hundred ninety-eight patients with ankylosing spondylitis and 61 with non-radiographic axial spondyloarthritis completed the Jenkins Sleep Evaluation Questionnaire. Measures of disease activity, mobility, function, mood, fatigue, quality of life, work productivity, night-time pain and general health were gathered...
January 19, 2018: Clinical Rheumatology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"